HARRY C DIETZ, M.D.
Medical Practice at Wolfe St, Baltimore, MD
License number
Maryland D38909
Category
Medical Practice
Type
Pediatrics
License number
Maryland D38909
Category
Medical Practice
Type
Clinical Genetics (M.D.)
Address
Address
600 N Wolfe St, Baltimore, MD 21287
Phone
(410) 955-3071
Personal information
See more information about HARRY C DIETZ at radaris.comName
Address
Phone
1104 Ryegate Rd, Towson, MD 21286
1103 Ryegate Rd, Towson, MD 21286
1104 Ryegate Rd, Towson, MD 21286
Towson, MD
Organization information
See more information about HARRY C DIETZ at bizstanding.comHarry C Dietz MD
733 N Broadway, Baltimore, MD 21205
Industry:
Physician - Research
Phone:
(410) 614-0701 (Phone)
Office Manager:
Debbie Churchill (Office Manager)
Categories:
Pediatrics Physicians & Surgeons
Professional information
See more information about HARRY C DIETZ at trustoria.com
Harry C Dietz, Baltimore MD
Harry C Dietz, Baltimore MD
Specialties:
Pediatrics, Medical Genetics, Clinical Genetics, M.D., Cardiology
Work:
The Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD 21287 Johns Hopkins University
733 N Broadway, Baltimore, MD 21205
600 N Wolfe St, Baltimore, MD 21287 Johns Hopkins University
733 N Broadway, Baltimore, MD 21205
Education:
Upstate Medical University Physical Medicine and Rehabilitation (1984)
Detection Of A Predisposition For The Development Of Coronary Artery Disease
Detection Of A Predisposition For The Development Of Coronary Artery Disease
US Patent:
2005005, Mar 10, 2005
Filed:
Nov 13, 2003
Appl. No.:
10/714470
Inventors:
Harry Dietz - Towson MD, US
Dan Arking - Baltimore MD, US
Dan Arking - Baltimore MD, US
International Classification:
C12Q001/68, C12P019/34
US Classification:
435006000, 435091200
Abstract:
Methods and assays are disclosed for predicting a patient's predisposition for developing coronary artery disease or related vascular disorders. The methods comprise obtaining a biological sample from a patient and determining the presence or absence of the KL-VS allele which is linked with coronary artery disease. Detection of the allele is indicative of a predisposition or propensity to develop coronary artery disease. Kits for the detection of coronary artery disease are additionally provided.
Harry C Dietz, Baltimore MD
Harry C Dietz, Baltimore MD
Specialties:
Pediatrician
Address:
600 N Wolfe St, Baltimore, MD 21287
733 N Broadway, Baltimore, MD 21205
600 N Wolfe, Baltimore, MD 21287
733 N Broadway, Baltimore, MD 21205
600 N Wolfe, Baltimore, MD 21287
Education:
State University of New York, Upstate Medical University - Doctor of Medicine
Board certifications:
American Board of Pediatrics Certification in Pediatrics
Methods And Compositons Featuring Tgf-Beta Antagonists For The Treatment Of Marfan Syndrome And Associated Disorders
Methods And Compositons Featuring Tgf-Beta Antagonists For The Treatment Of Marfan Syndrome And Associated Disorders
US Patent:
8597646, Dec 3, 2013
Filed:
Oct 25, 2006
Appl. No.:
12/084098
Inventors:
Harry C. Dietz - Towson MD, US
Daniel P. Judge - Baltimore MD, US
Enid R. Neptune - Baltimore MD, US
Ronald Cohn - Pikesville MD, US
Jennifer Habashi - Annapolis MD, US
Daniel P. Judge - Baltimore MD, US
Enid R. Neptune - Baltimore MD, US
Ronald Cohn - Pikesville MD, US
Jennifer Habashi - Annapolis MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 39/395, C07K 16/22, C07K 14/495
US Classification:
4241451, 4241331, 4241351, 4241581, 5303871, 53038736, 53038823, 5303892
Abstract:
The instant invention provides methods and compositions for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The invention further provides pharmaceutical compositions and kits for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions.
Mammalian Regulator Of Nonsense-Mediated Rna Decay
Mammalian Regulator Of Nonsense-Mediated Rna Decay
US Patent:
6048965, Apr 11, 2000
Filed:
Mar 17, 1999
Appl. No.:
9/270984
Inventors:
Harry C. Dietz - Towson MD
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
C07K 1447
US Classification:
530350
Abstract:
All eukaryotes that have been studied to date possess the ability to detect and degrade transcripts that contain a premature signal for the termination of translation. This process of nonsense-mediated RNA decay (NMRD) has been most comprehensively studied in the yeast, Saccharomyces cerevisiae where at least three trans-acting factors (Upf1p through Upf3p) are required. The present invention provides cDNAs encoding human and murine RENT1 (regulator of nonsense transcripts). rent1 is the first identified mammalian protein that contains all of the putative functional elements in Upf1p including zinc finger-like motifs and NTPase domains as well as all motifs common to members of helicase superfamily I. Moreover, expression of a chimeric protein, containing the central region of RENT1 flanked by the extreme N- and C-termini of Upf1p, complements the Up1p-deficient phenotype in yeast.
Delivery Construct For Antisense Nucleic Acids And Methods Of Use
Delivery Construct For Antisense Nucleic Acids And Methods Of Use
US Patent:
6924096, Aug 2, 2005
Filed:
Sep 29, 1998
Appl. No.:
09/163289
Inventors:
Harry C. Dietz - Towson MD, US
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
C12Q001/68, A61K048/00
US Classification:
435 6, 536 231, 536 245, 435325, 435375
Abstract:
A novel nucleic acid construct for delivery of antisense targeting sequences is provided. The construct includes intact stem loop structures and an antisense nucleic acid. Optionally, a ribozyme nucleic acid is included in the construct. The construct is useful for inhibition of selected genes in a cell. This allele-specific targeting is also useful in combination with replacement gene therapy.
Methods Of Identifying Compounds That Inhibit Nonstop Degradation Of Mrna
Methods Of Identifying Compounds That Inhibit Nonstop Degradation Of Mrna
US Patent:
2004007, Apr 15, 2004
Filed:
Apr 16, 2003
Appl. No.:
10/417354
Inventors:
Harry Dietz - Towson MD, US
Pamela Frischmeyer - Baltimore MD, US
Roy Parker - Tucson AZ, US
Ambrosius Van Hoof - Pearland TX, US
Pamela Frischmeyer - Baltimore MD, US
Roy Parker - Tucson AZ, US
Ambrosius Van Hoof - Pearland TX, US
International Classification:
C12Q001/68, A61K031/704
US Classification:
435/006000, 536/037000, 514/036000
Abstract:
The invention provides screening methods for the identification of compounds that inhibit nonstop degradation of mRNA, including compounds that inhibit the exosome. The invention further provides methods of treatment for genetic disorders caused by premature termination codons.
Methods And Compositions For Identifying Disease Genes Using Nonsense-Mediated Decay Inhibition
Methods And Compositions For Identifying Disease Genes Using Nonsense-Mediated Decay Inhibition
US Patent:
2004016, Aug 19, 2004
Filed:
Apr 14, 2004
Appl. No.:
10/474553
Inventors:
Harry Dietz - Towson MD, US
Eric Noensie - New York NY, US
Eric Noensie - New York NY, US
International Classification:
C12Q001/68
US Classification:
435/006000
Abstract:
The invention provides compositions and methods for diagnostic and therapeutic applications of gene identification by nonsense-mediated decay inhibition (GINI). The approach allows the rapid identification of the genes and genetic lesions responsible for monogenic as well as polygenic human genetic disorders. In addition, the approach supports diagnostic typing and therapeutic selection for human cancers and other disorders arising as a result of gene mutations.
Delivery Construct For Antisense Nucleic Acids And Methods Of Use
Delivery Construct For Antisense Nucleic Acids And Methods Of Use
US Patent:
2005002, Jan 27, 2005
Filed:
Aug 27, 2004
Appl. No.:
10/927934
Inventors:
Harry Dietz - Towson MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
C07H021/02, A01H001/00, C12N015/82, A61K048/00
US Classification:
514044000, 800286000, 536023100
Abstract:
A novel nucleic acid construct for delivery of antisense targeting sequences is provided. The construct includes intact stem loop structures and an antisense nucleic acid. Optionally, a ribozyme nucleic acid is included in the construct. The construct is useful for inhibition of selected genes in a cell. This allele-specific targeting is also useful in combination with replacement gene therapy.
Delivery Construct For Antisense Nucleic Acids And Methods Of Use
Delivery Construct For Antisense Nucleic Acids And Methods Of Use
US Patent:
5814500, Sep 29, 1998
Filed:
Oct 31, 1996
Appl. No.:
8/742943
Inventors:
Harry C. Dietz - Towson MD
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
C12Q 102
US Classification:
4351723
Abstract:
A novel nucleic acid construct for delivery of antisense targeting sequences is provided. The construct includes intact stem loop structures and an antisense nucleic acid. Optionally, a ribozyme nucleic acid is included in the construct. The construct is useful for inhibition of selected genes in a cell. This allele-specific targeting is also useful in combination with replacement gene therapy.
Medical Practice licenses in Maryland
JULIA RACHEL NOETHER, Medical Practice, 600 N Wolfe St Department Of Pediatrics, Baltimore, MD 21287